Literature DB >> 22115849

Can Parkinson's disease pathology be propagated from one neuron to another?

Christopher J R Dunning1, Juan F Reyes, Jennifer A Steiner, Patrik Brundin.   

Abstract

Parkinson's disease is the second most prevalent neurodegenerative disease, yet despite this, very little is known about the underlying cellular mechanisms. Initially it was thought to be a disease primarily involving loss of dopaminergic neurons in the substantia nigra pars compacta. Recent studies, however, have focused on observations that aggregated α-synuclein protein, the major component of Lewy bodies, is found throughout the nervous system. It is speculated that misfolded α-synuclein transfers between cells in a prion-like manner, thereby mediating the spread of the neuropathology. In this review, we discuss the staging (according to Braak) of Parkinson pathology and the concept describing the disease progression from one region of the brain to the other. We highlight how α-synuclein might be responsible for the spread of the disease. We compare the idea of a prion-like mechanism contributing to Parkinson's disease to emerging concepts that other proteins participate in similar processes in other neurodegenerative diseases. We then examine the future implications of a critical role in disease pathogenesis of α-synuclein for the classification, diagnosis and treatment of Parkinson's disease in the future.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22115849     DOI: 10.1016/j.pneurobio.2011.11.003

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  40 in total

Review 1.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 2.  The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.

Authors:  Oliver D King; Aaron D Gitler; James Shorter
Journal:  Brain Res       Date:  2012-01-21       Impact factor: 3.252

Review 3.  Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents.

Authors:  Hiroyasu Sato; Takeo Kato; Shigeki Arawaka
Journal:  Mol Neurobiol       Date:  2014-08-21       Impact factor: 5.590

Review 4.  Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-11-01       Impact factor: 10.005

5.  Adsorption of α-synuclein to supported lipid bilayers: positioning and role of electrostatics.

Authors:  Erik Hellstrand; Marie Grey; Marie-Louise Ainalem; John Ankner; V Trevor Forsyth; Giovanna Fragneto; Michael Haertlein; Marie-Therese Dauvergne; Hanna Nilsson; Patrik Brundin; Sara Linse; Tommy Nylander; Emma Sparr
Journal:  ACS Chem Neurosci       Date:  2013-07-25       Impact factor: 4.418

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 8.  Inflammatory mediators as biomarkers in brain disorders.

Authors:  Domenico Nuzzo; Pasquale Picone; Luca Caruana; Sonya Vasto; Annalisa Barera; Calogero Caruso; Marta Di Carlo
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 9.  [Gastrointestinal dysfunction in idiopathic Parkinson's disease].

Authors:  K Del Tredici; W H Jost
Journal:  Nervenarzt       Date:  2012-10       Impact factor: 1.214

Review 10.  Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Authors:  Nandakumar S Narayanan; Robert L Rodnitzky; Ergun Y Uc
Journal:  Rev Neurosci       Date:  2013       Impact factor: 4.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.